Showing results (1551-1560 of 1,686) with videos related to
Sort By:
Pageof 169
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.The American Journal of Cardiology|December 18, 2023
Five-Year Follow-Up from the CoreValve Expanded Use Transcatheter Aortic Valve-in-Surgical Aortic Valve StudyTanvir K Bajwa, Roger J Laham, Kamal Khabbaz, et al.JAMA|April 10, 1996
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registryP H Stone, B Thompson, H V Anderson, et al.JAMA|February 7, 2002
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent interventionJ Conor O'Shea, Christopher E Buller, Warren J Cantor, et al.The American Journal of Cardiology|June 14, 2005
Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromesKenneth W Mahaffey, Matthew T Roe, Rakhi Kilaru, et al.Cardiovascular Revascularization Medicine : Including Molecular Interventions|November 17, 2020
Three-Year Outcomes With a Contemporary Self-Expanding Transcatheter Valve From the Evolut PRO US Clinical StudyMoritz C Wyler von Ballmoos, Michael J Reardon, Mathew R Williams, et al.Journal of Clinical Microbiology|April 11, 2014
Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United StatesPaschalis Vergidis, Raymund R Razonable, L Joseph Wheat, et al.Circulation. Cardiovascular Interventions|March 7, 2026
Hospital-level Variability in NSTEMI Management: Findings from the NCDR Chest Pain-MI RegistryYasser M Sammour, John A Spertus, Nathaniel R Smilowitz, et al.Circulation|September 7, 2000
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialA M Lincoff, R A Harrington, R M Califf, et al.Lancet (London, England)|April 12, 2001
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational studyH D Aronow, E J Topol, M T Roe, et al.Pageof 169